PHILADELPHIA, Feb. 14, 2024 (GLOBE NEWSWIRE) -- Kaskela Law LLC announces that it has commenced an investigation into Integra LifeSciences Holdings Corp. (NASDAQ:IART) ("Integra") on behalf of the company's long-term investors.
Recently a securities fraud complaint was filed against Integra on behalf of investors who purchased shares of the company's stock between March 11, 2019 and May 22, 2023 (the "Class Period"). According to the complaint, during the Class Period Integra and certain of the company's senior executive officers issued a series of materially false and misleading statements to investors.
As detailed in the complaint, on October 9, 2018, the FDA began an inspection of the company's Boston Facility, during which it observed that Integra's quality systems and manufacturing conditions were "not in conformity with the current good manufacturing practice requirements of the Quality System Regulation." As a result, on November 2, 2018, the FDA issued a Notice of Inspectional Observations on Form 483 to put Integra on notice of those violations. After receiving ...
IART) and Encourages Long-Term Investors to Contact the Firm>Full story available on Benzinga.com